Platelets, D-dimer and Lactate Dehydrogenase (LDH) as Cost Effective Biomarkers for the detection of COVID-19-Associated Coagulopathy (CAC)
Platelets, D-dimer and Lactate Dehydrogenase (LDH) as Cost Effective Biomarkers for the detection of COVID-19-Associated Coagulopathy (CAC)
SADAF IFTIKHAR1, SAMAN SHAHID2*, MUHAMMAD UMAR HASSAN1 & UBAID ULLAH3
ABSTRACT
We highlighted the role of D-dimers, platelet count and LDH (lactate dehydrogenase) as primary biomarkers in diagnosing the COVID-19-associated coagulopathy (CAC) in severe and critical cases. 141 COVID-19 patients of severe and critical categories, were enrolled from an epicenter tertiary care hospital. The mean values of platelets were found normal, whereas, the mean values of LDH were found elevated in both severe and critical cases. There was no patient with low value of LDH in both groups. 87% patients were having high values of LDH in severe cases, whereas, 98% patients were having high values of LDH in critical cases. Majority patients were having normal value of platelet counts. 43% critically infected patients were having raised D-dimers, whereas, 38% raised D-dimers were found in severely infected patients. According to t-test, severe and critical cases were not found significantly different in platelet counts and LDH values. In developing countries, LDH along with platelet count and D-dimers can make a cost effective trio for an earliest detection of COVID-19-associated coagulopathy (CAC). Regular monitoring of these biomarkers can prompt early detection and timely management of CAC.
To share on other social networks, click on any share button. What are these?
